Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients

Journal of the National Medical Association

Volumn 92, Issue 9, 2000, Pages 445-449

  Asbell, Sucha O ^b   Rajmane, Kiran C ^b   Montesano, Angelica T ^b   Zeitzer, Kenneth L ^b   Asbell, Matthew D ^b   Vijayakumar, Srinivasan ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

African Americans; Androgen; Antigen; Prostate cancer

Indexed keywords

ANDROSTANOLONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TUMOR MARKER;

AFRICAN AMERICAN; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CAUCASIAN; ETHNOLOGY; HUMAN; MALE; NEGRO; PROSTATE TUMOR;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CASE-CONTROL STUDIES; DIHYDROTESTOSTERONE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 0034265496     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993;2:27-32.
2. George FW, Russell DW, Wilson JD. Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5a-reductase. Proc Natl Acad Sci USA. 1991;88:8044-8047.
3. Lamb JC, Levy MA, Johynson RK, Isacs JT. Response of rat and human prostatic cancers to the novel 5a-reductase inhibitor, SK&F 105657. Prostate. 1992;21:15-34.
4. Andersson SO, Adami HO, Bergstrom R, Wide L. Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer: a population-based case-control study. Br J Cancer. 1993;68:97-102.
5. Ross RK, Bernstein L, Lobo RA, et al. 5a-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339:887-889.
6. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate specific antigen values at the time of prostate cancer diagnosis in Afro-American men. JAMA. 1995;274:1277-1281.
7. Asbell SO, Vijayakumar S. Racial differences in prostate specific antigen levels in patients with local-regional prostate cancer. Prostate. 1997;31:42-46.
8. Vijayakumar S, Karrison T, Weichselbaum RR, Chan S, Quadri SF, Awan AM. Racial differences in prostate specific antigen levels in patients. Cancer Epidemiol Biomarkers Prev. 1992;1:541-545.
9. Eastham JA, May RA, Whatley T, Crow A, Venable DD, Sartor O. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst. 1998;90:756-760.
10. Ross R, Bernstein L, Judd H, Hanisch R, Pike MC, Henderson BE. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986;76:45-48.
11. Ellis L, Nyborg H. Racial/ethnic variation in male testosterone levels: a probable contributor to group differences in health. Steroids. 1992;57:72-75.
12. Vijayakumar S, Quadri SF, Dong L, et al. Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. J Natl Med Assoc. 1995;87:813-819.
13. Wu AH, Whittemore AS, Kolonel LN, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995;4:735-741.
14. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092-1098.
15. Vermuelen A. Clinical review 24: androgens in the aging male. J Clin Endocrinol Metab. 1991;73:221-224.
16. Carlstrom K, Eriksson A, Stege R, Rannevik G. Relationship between serum testosterone and sex hormone binding globulin in adult men with intact or absent gonadal function. Int J Androl. 1990;13:67-73.
17. Wilson DW, Harper ME, Jensen HM, et al. A prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation. Prostate. 1985;7:131-141.
18. Seal US, and the VA Uro-Oncology Research Group. FSH and LH elevation after radiation for treatment of cancer of the prostate. Invest Urol. 1979;16:278-280.
19. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for serum prostate specific antigen in black men. N Engl J Med. 1996;355: 304-310.
20. Vijayakumar S, Weichselbaum R, Vaida F, Dale W, Hellman S. Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J from Sci Am. 1996;2:225-233.
21. Abdalla I, Ray P, Ray V, Vaida F, Vijayakumar S. Comparison of serum prostate-specific antigen levels and PSA density in African-American, white, and hispanic men without prostate cancer. J Urol. 1998;51:300-305.
22. Abdalla I, Ray P, Vijayakumar S. Race and serum prostate-specific antigen levels: current status and future directions. Semin Urologic Oncol. 1998;16:207-213.